<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Monoclonal or polyclonal antibodies have been suggested as prophylactic and therapeutic tools (targeting hemagglutinin binding) against some viral infections, such as influenza.
 <xref rid="bib48" ref-type="bibr">
  <sup>48</sup>
 </xref> Current efforts in developing monoclonal and polyclonal antibodies against coronaviruses mainly target MERS-CoV.
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref> For example, a human polyclonal antibody SAB-301 (50 mg/kg) that was generated in transchromosomic cattle was observed to be well tolerated and safe in healthy participants of a phase 1 clinical trial.
 <xref rid="bib49" ref-type="bibr">
  <sup>49</sup>
 </xref> However, Cockrell et al. (2016) observed that immune-based therapy with human monoclonal antibodies only provided protection against early stage disease caused by MERS-CoV in mouse models.
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib50" ref-type="bibr">
  <sup>50</sup>
 </xref>
</p>
